Trial Profile
A Prospective Pragmatic Clinical Trial Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Jan 2019 Status changed from recruiting to completed.
- 03 Dec 2018 Planned End Date changed from 1 Dec 2018 to 28 Nov 2018.
- 09 Dec 2015 Planned End Date changed from 1 Mar 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.